Published: Jun, 2018
The global erythropoietin drugs market is anticipated to experience a surge in product development taken up by the firms operating in the regional and global market. Players seem to be looking for more number of distributors, owing to increase in competition among the peers in the market. This in turn, show the increase in number of distribution channel in the market, contributing in the overall growth of the market. Key players are investing into strategic mergers and acquisitions in order to gain better return on investment (ROI). This is encouraging them to come up with more cost-effective and efficient products. Moreover, government initiatives regarding the research and development activities is another factor bolstering the demand for erythropoietin drugs in the market.
According to Transparency Market Research (TMR), the global erythropoietin drugs market is expected to expand at a steady CAGR of 7.5% within the forecast period from 2017 to 2025. By the end of 2025, the market is valued to around worth of US$19.3 bn. Based on drug class, the market is segmented into epoetin beta, epoetin alfa, darbepoetin alfa, and others. Among these, in 2016, the Epoetin alfa was the leading segment. The segment is foreseen to dominate in the forecast period as well, as far as revenues are concerned. It is anticipated to remain dominant in the forecast period, in terms of revenues. The segment of Epoetin alfa is generally used to treat chronic renal failure, and cancer chemotherapy. Geographically, North America emerged as a leading region, back in 2016, and is likely to sustain its dominance in coming year as well. The regional growth is credited to rise in approvals related with erythropoietin drugs, and fee waivers and reimbursement policies offered by the governments.
Usage of Erythropoietin Drugs in Cancer Treatment to Augment Market Growth
The significant rise in prevalence of chronic illness all over the world is one of the major factor that is anticipated to surge the demand for global erythropoietin drugs market. The usage of erythropoietin drugs in cancer treatment is expected to be responsible for the notable number of market share in forthcoming years due to their promising pipeline drugs. However, the maximum amount of overall share is credited to the rise in number of people suffering from renal illness and other kidney diseases.
Improper Price Capping Regulations to Hamper Market Growth
The global erythropoietin drugs market is prognosticated to be hindered by improper price cap rules and regulations in some regions, such as Europe. The growth is also appearing to be hampered due to low-grade healthcare services available in developing nations. Along with this, the lack of proper diagnosis technique are also expected to slow down the market growth of erythropoietin drugs.
Nevertheless, as the drugs are the most preferred method to treat a chronic ailments and tumors, the global erythropoietin drugs market is till anticipated to flourish substantially in the coming years. Moreover, the erythropoietin drugs are also used to cure anemia, which is another factor accelerating the demand in the market.
This analysis is based on a recent market research report by Transparency Market Research, titled, “Erythropoietin Drugs Market (Drug Class - Epoetin Alfa, Epoetin Beta, and Darbepoetin Alfa; Drug Type - Biologics and Biosimilar; Drug Application - Cancer, Renal Disease, Hematology, Neurology, and Surgery and Wound Healing; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025.”
- The significant rise in prevalence of chronic illness all over the world is one of the major factor that is anticipated to surge the demand for global erythropoietin drugs market.
- The maximum amount of overall share is credited to the rise in number of people suffering from renal illness and other kidney diseases.
The global erythropoietin drugs market has been segmented as presented below:
Global Erythropoietin Drugs Market by Drug Class
- Epoetin Alfa
- Epoetin Beta
- Darbepoetin Alfa
Global Erythropoietin Drugs Market by Drug Type
Global Erythropoietin Drugs Market by Drug Application
- Renal Disease
- Surgery and Wound Healing
Global Erythropoietin Drugs Market by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Erythropoietin Drugs Market by Geography
- North America
- Rest of Europe
- Asia Pacific (APAC)
- Australia and New Zealand
- Rest of APAC
- Latin America (LATAM)
- Rest of LATAM
- Middle East and Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453